Sengenics Launches New Autoantibody Biomarker Database to Enhance Development of Diagnostics and Therapeutics

Share Article

The Symphoni™ database comprises autoantibody profiles of more than 10,000 patients across 50 different diseases, which could serve as a powerful resource to identify truly disease-specific biomarker signatures.

Sengenics, the functional proteomics company, today announced the launch of its new autoantibody database, Symphoni™. The database comprises autoantibody profiles of more than 10,000 patients of various ethnicities (Asian, Caucasian and African-American) across 50 different diseases. It was created by collating and annotating true positive and true negative autoantibody signals generated from multiple studies using the Immunome protein array, which contains proteins expressed using the patented KREX™ technology.

KREX™ utilises the Biotin Carboxyl Carrier Protein (BCCP) as a folding marker and protein solubility enhancer. The success rate for expression of correctly folded and soluble proteins using KREX™ exceeds 98%. The technology can be applied in a highly parallelised pipeline resulting in high-throughput, highly consistent production of full-length, correctly folded and functionally validated proteins for autoantibody biomarker discovery. The KREX™ technology has also been used for making custom protein arrays for vaccine target identification, protein-protein interactions and on-array functional assays to screen drugs.

Sengenics’ CSO, Dr Jonathan Blackburn said, “Symphoni™ was developed with the primary aim of enhancing the specificity of autoantibody biomarker discovery studies by allowing our collaborators to screen for disease-specific biomarkers using KREX™ and to then filter out generic hits that are age-related or that are non-specific morbidity biomarkers which overlap different diseases. Given that all the biomarker hits identified using KREX™ are against correctly folded proteins, the overall quality of the database is very high. Symphoni™ should therefore serve as a powerful resource to identify those biomarker signatures which are truly disease-specific, thereby enabling researchers to focus downstream efforts on valid, clinically translatable autoantibody biomarkers.”

The Symphoni™ database will be made accessible to collaborators, partners and licensees of the Sengenics Technology Access Program (iTAP).

About Sengenics

Sengenics is a functional proteomics company that leverages its patented KREX™ technology for production of full-length, correctly folded and functional proteins. KREX™ is a patented proteomics technology which was spun out from research that was commercialised as a joint collaboration between the University of Oxford and the University of Cambridge. The three key applications of the KREX™ technology are; discovery of autoantibody biomarkers for human diseases, autoantibody-based immunotoxicity profiling of cancer immunotherapy patients and pharmaceutical industry-specific applications such as high-throughput SAR screening, predictive toxicology and antibody generation using KREX™ proteins.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Farah Elena
Sengenics
+60 127198656
Email >
Visit website